Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.38 |
| ▸ | HTR3B | O95264 | 3/20 | 0.38 |
| ▸ | HTR3A | P46098 | 3/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12076886 | 1.00 | KCNH2 (0.51) | KCNH2OPRK1HCRTR1HCRTR2LOX | |
| SCHEMBL12077152 | 0.88 | KCNH2 (0.49) | KCNH2OPRK1HCRTR1HCRTR2LOX | |
| SCHEMBL12077151 | 0.88 | KCNH2 (0.49) | KCNH2OPRK1HCRTR1HCRTR2LOX | |
| SCHEMBL12077027 | 0.87 | KCNH2 (0.50) | KCNH2OPRK1HCRTR1HCRTR2LOX | |
| SCHEMBL12077026 | 0.87 | KCNH2 (0.50) | KCNH2OPRK1HCRTR1HCRTR2LOX | |
| SCHEMBL12094630 | 0.85 | GPR119 (0.49) | KCNH2OPRK1HCRTR1HCRTR2LOX | |
| SCHEMBL12076981 | 0.81 | KCNH2 (0.51) | KCNH2OPRK1HCRTR1HCRTR2GPR119 | |
| SCHEMBL12076980 | 0.81 | KCNH2 (0.51) | KCNH2OPRK1HCRTR1HCRTR2GPR119 | |
| SCHEMBL12077501 | 0.81 | OPRK1 (0.46) | KCNH2OPRK1GPR119OPRM1 | |
| SCHEMBL12077499 | 0.81 | OPRK1 (0.46) | KCNH2OPRK1GPR119OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2500345-B1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | KCNH2 336/4885OPRK1 495/4885HCRTR1 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.